供者人类白细胞抗原-Bw4等位基因对单倍体移植中自然杀伤细胞重建及移植相关死亡率的影响
本研究前瞻性入组32例接受母体或旁系供者非去T细胞单倍体移植患者(队列1)评估供者HLA-Bw4对NK细胞重建的促进作用,并回顾性分析278例同类移植患者(队列2)分析供者HLA-Bw4对移植预后的影响,同时比较接受与未接受PT-Cy情况下供者HLA-Bw4对预后的影响差异。
要点
- 编码HLA-Bw4的供者促进NK细胞重建和功能恢复,PT-Cy体内应用未影响该促进作用。
- 编码HLA-Bw4的供者与移植相关死亡率降低相关,尤其感染相关TRM降低。
- PT-Cy体内应用未影响供者HLA-Bw4降低TRM的能力。
核心结论
- 在来自母体或旁系供者的非体外去T细胞单倍体移植中,编码HLA-Bw4的供者有助于快速NK细胞重建和功能恢复,并与较低的TRM(尤其感染相关TRM)显著相关。
- 供者HLA-Bw4表达对单倍体移植患者临床结果具有重要意义,在供受者选择和移植策略中考虑供者HLA-Bw4可能具有临床意义。
研究设计与样本
- 前瞻性入组32例接受母体或旁系供者非去T细胞单倍体移植患者(队列1),评估供者HLA-Bw4表达对NK细胞重建的影响。
- 回顾性分析278例接受母体或旁系供者非去T细胞单倍体移植患者(队列2),分析供者HLA-Bw4对HSCT预后的影响。
- 分别比较接受PT-Cy和不接受PT-Cy情况下供者HLA-Bw4表达对HSCT预后影响的差异。
主要发现
- 编码HLA-Bw4的供者促进了NK细胞重建和功能恢复,PT-Cy体内应用未影响供者HLA-Bw4促进NK细胞重建。
- 编码HLA-Bw4的供者与TRM降低相关,尤其感染相关TRM降低;PT-Cy体内应用未影响供者HLA-Bw4降低TRM。
临床怎么用
- 作者认为,在供受者选择和移植策略中考虑供者HLA-Bw4可能具有临床意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the impact of donor human leukocyte antigen (HLA) -Bw4 expression on natural killer (NK) cell reconstitution and transplant outcomes in recipients undergoing haploidentical hematopoietic stem cell transplantation (HSCT) from maternal or related donors without ex vivo T-cell depletion. Methods: This study prospectively enrolled 32 patients who received T-replete haploidentical HSCT from maternal or collateral donors (cohort 1) to evaluate the facilitating effect of donor HLA-Bw4 expression on NK cell reconstitution. Furthermore, a retrospective analysis was conducted on 278 patients who underwent T-replete haploidentical HSCT from maternal or collateral donors (cohort 2) to analyze the impact of donor HLA-Bw4 expression on HSCT outcomes. Thus, a comparison was made between the effects of donor HLA-Bw4 expression on HSCT outcomes in patients receiving or not receiving post-transplant cyclophosphamide (PT-Cy) conditioning. Results: Donors expressing HLA-Bw4 alleles facilitated NK cell reconstitution and functional recovery, which remained unaffected by PT-Cy. Donors with HLA-Bw4 expression were associated with reduced transplant-related mortality (TRM), particularly mortality related to infections. The use of PT-Cy did not impact the ability of donor HLA-Bw4 to decrease TRM. Conclusion: In haploidentical HSCT from maternal or related donors without ex vivo T-cell depletion, the presence of donor HLA-Bw4 expression promotes rapid NK cell reconstitution and functional recovery and is significantly associated with lower TRM, especially infection-related mortality. These findings underscore the clinical significance of donor HLA-Bw4 expression in patients who underwent HSCT. Hence, the consideration of donor HLA-Bw4 in recipient selection and HSCT strategies holds important clinical implications. 目的: 探讨在接受来自母体或旁系供者的非去T细胞单倍体造血干细胞移植时,供者HLA-Bw4表达对NK细胞重建和移植预后的影响。 方法: 本研究前瞻性入组了32例接受来自母体或旁系的供者非去T细胞单倍体移植患者(队列1),评估供者HLA-Bw4表达对NK细胞重建的影响;同时回顾性研究了278例接受来自母体或旁系的供者非去T细胞单倍体移植患者(队列2),分析供者HLA-Bw4对HSCT预后的影响。同时还分别比较了在接受移植后环磷酰胺(PT-Cy)和不接受PT-Cy的情况下,供者HLA-Bw4表达对HSCT预后影响的差异。 结果: 编码HLA-Bw4的供者促进了NK细胞的重建和功能恢复,PT-Cy体内应用并未影响供者HLA-Bw4促进NK细胞重建。编码HLA-Bw4的供者与移植相关死亡率(Transplantation-related mortality,TRM),尤其是感染相关的TRM(infection-related TRM)降低相关,PT-Cy体内应用并未影响供者HLA-Bw4降低TRM。 结论: 在进行来自母体或旁系供者的非体外去T细胞单倍体移植时,编码HLA-Bw4的供者有助于快速NK细胞重建和功能恢复,并且与较低的TRM(尤其是感染相关TRM)显著相关。这些结果表明,供者HLA-Bw4的表达对于单倍体移植患者的临床结果具有重要意义。因此,在供受者选择和移植策略中,考虑供者HLA-Bw4可能具有临床意义。.
引用
- Zhao M, Xu ZL, Yu XX, et al. [The impact of donor human leukocyte antigen-Bw4 allele on natural killer cell reconstitution and transplant-related mortality in haploidentical transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38964919. doi:10.3760/cma.j.cn.121090-20240314-00094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。